Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ZYME vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZYME Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

ZYME Overall Winner 6-Pillar Tally: ZYME 6 – 0 NUVB Matrix Metrics: ZYME 8 – 2 NUVB

As of Nov 20, 2026, Zymeworks Inc. (ZYME) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZYME carries a Unified Composite Score of 59.5/100 (HOLD) at $26.14 (55.0x Forward P/E, 22.6% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ZYME 59.5/100 HOLD), ZYME captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.6% vs. -61.2% operating margin) and revenue trajectory (+828.7% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: ZYME trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZYME vs NUVB
ZYME NASDAQ Head-to-Head Winner
Zymeworks Inc.
Pharmaceutical Preparations
$26.14
-2.68% 1D
Market Cap $1.9B
TTM Revenue $266M
Forward P/E 55.0x
Beta / 30D Vol 0.87β · 56% Vol
Unified Composite Score
59.5 / 100 HOLD
Tech 60.0 Fund 59.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.1 · SMA20: $28.36 · SMA50: $27.20
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (ZYME 6 – 0 NUVB)

Columns: Metric · ZYME · NUVB
1. Valuation Multiples ZYME
Forward P/E 55.0x N/M
Trailing P/E 50.7x N/M
PEG Ratio N/M N/M
EV / Revenue 6.8x 7.4x
2. Growth & Scale ZYME
Revenue Growth (YoY) +828.7% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $266M $202M
Market Cap $1.9B $1.3B
3. Profitability & Quality ZYME
Gross Margin 51.7% 85.8%
Operating Margin 22.6% -61.2%
Net Profit Margin 16.3% -67.4%
Return on Equity (ROE) 15.0% -49.1%
4. Balance Sheet & Cash Flow ZYME
Cash Generation (TTM) -$113M -$108M
Cash Flow Margin -42.5% -53.6%
Net Cash / Leverage $47M Net Cash $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZYME
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 350.4% (45th %ile) 65.2% (26th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ZYME
OpEx & R&D Intensity 29.1% of Rev ($77M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZYME (8) vs NUVB (2)
Institutional Metric ZYME NUVB Criterion Row Edge
Market Capitalization
Scale
$1.9B $1.3B Larger Scale ZYME
Trailing P/E Ratio
Valuation
50.7x N/M Lower Multiple ZYME
Forward P/E Ratio
Valuation
55.0x N/M Lower Multiple ZYME
Revenue Growth (YoY)
Growth
+828.7% +242.6% Higher Growth ZYME
Operating Margin (TTM)
Profitability
22.6% -61.2% Higher Margin ZYME
Net Profit Margin
Profitability
16.3% -67.4% Higher Margin ZYME
Return on Equity (ROE)
Capital Efficiency
15.0% -49.1% Higher ROE ZYME
52-Week Range Position
Momentum
44% ($22–$32) 2% ($4–$10) Stronger Trend ZYME
Beta / 30D Volatility
Risk Regime
0.87β · 56% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
59.5 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$266M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.7% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$113M ($47M Net Cash) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZYME +11.06 pp
ZYME: -8.09% · NUVB: -19.15%
3M Horizon ZYME +34.65 pp
ZYME: -9.14% · NUVB: -43.79%
6M Horizon ZYME +21.56 pp
ZYME: +2.07% · NUVB: -19.49%
1Y Horizon ZYME +62.51 pp
ZYME: +15.66% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZYME Revenue NUVB Revenue ZYME Op. Margin NUVB Op. Margin Margin Leader
FY2020 $40M N/A -481.3% N/A ZYME
FY2021 $30M N/A -808.2% N/A ZYME
FY2022 $410M N/A 31.6% N/A ZYME
FY2023 $80M N/A -181.6% N/A ZYME
FY2024 $80M $10M -179.7% -7527.3% ZYME
FY2025 $110M $60M -87.3% -338.7% ZYME

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZYME CONSOLIDATION
56d in phase · OBV NEUTRAL
Current IV 350.4%
IV Percentile 45th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZYME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZYME Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 22.6% operating margin.
OpEx & R&D Reinvestment 29.1% of Rev ($77M)
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZYME vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Zymeworks Inc. (ZYME) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZYME carries a Unified Composite Score of 59.5/100 (HOLD) at $26.14 (55.0x Forward P/E, 22.6% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ZYME 59.5/100 HOLD), ZYME captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.6% vs. -61.2% operating margin) and revenue trajectory (+828.7% vs. +242.6% YoY). Technical & Structure Timing Caution: ZYME trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZYME leads the Growth & Scale pillar: ZYME posts +828.7% YoY revenue growth and +0.0% YoY earnings growth on $266M TTM revenue (51.7% gross margin, 22.6% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ZYME cumulative revenue shifted +175.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, ZYME deploys 29.1% of Rev ($77M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

ZYME screens cheaper on headline valuation multiples. ZYME trades at 55.0x Forward P/E, 50.7x Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-42.5% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZYME (15.0% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ZYME carries 350.4% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 56% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.